PMID- 36896932
OWN - NLM
STAT- Publisher
LR  - 20230310
IS  - 1130-0108 (Print)
IS  - 1130-0108 (Linking)
DP  - 2023 Mar 10
TI  - Efficacy and safety of mesenchymal stem cells in the treatment of perianal 
      fistulas in Crohn's disease: a meta-analysis of randomized controlled trials.
LID - 10.17235/reed.2023.9213/2022 [doi]
AB  - OBJECTIVES: Local mesenchymal stem cell (MSC) therapy for perianal fistulas in 
      Crohn's disease (CD) has yielded promising results, but it still remains 
      controversial. In this study, we aimed to conduct a meta-analysis of randomized 
      controlled trials (RCTs) to evaluate the efficacy and safety of MSC therapy for 
      perianal CD (pCD). METHODS: RCTs reporting MSC therapy for perianal fistulas in 
      CD were searched and included. The effectiveness and safety data were analyzed 
      using RevMan 5.3. RESULTS: A total of 7 RCTs were included in this meta-analysis. 
      The analysis showed that patients receiving MSC therapy presented a higher 
      healing rate (HR) of pCD than those in the control group (odds ratio (OR)=1.42; 
      95% confidence interval (CI) 1.18, 1.71; P=0.0002). Compared with placebo (saline 
      solution), MSC therapy improved the HR of pCD (OR=1.85; 95% CI 1.32, 2.60; 
      P=0.0004). MSC therapy showed significant long-term efficacy (OR=1.36; P=0.009; 
      95% CI 1.08, 1.71). When MRI was used to evaluate fistula healing, a pooled 
      analysis showed that the MSC group achieved a higher HR than the control group 
      (OR=1.95; 95% CI 1.33, 2.87; P=0.0007). Allogeneic MSC therapy was superior to 
      the control treatment in improving HR (OR = 1.97; 95% CI 1.40, 2.75; P<0.001). 
      Furthermore, no significant differences were observed between MSC therapy and 
      placebo in terms of adverse events (AEs) (OR = 1.16; 95% CI 0.76, 1.76; P = 
      0.48). None of the AEs were judged to be related to MSC treatment. CONCLUSIONS: 
      This meta-analysis of RCTs provided evidence that local MSC injection is safe and 
      efficacious for perianal fistulas in CD. In addition, this treatment has 
      favorable long-term efficacy and safety profiles.
FAU - Cheng, Fang
AU  - Cheng F
AD  - Gastroenterology, Zigong First People's Hospital, China.
FAU - Huang, Zhong
AU  - Huang Z
AUID- ORCID: 0000-0002-6580-3870
AD  - Gastroenterology, Zigong First People's Hospital.
FAU - Wei, Wei
AU  - Wei W
AUID- ORCID: 0000-0003-2714-3346
AD  - Gastroenterology, Zigong First People's Hospital.
FAU - Li, Zhi
AU  - Li Z
AUID- ORCID: 0000-0000-1933-0176
AD  - Gastroenterology, Zigong First People's Hospital.
LA  - eng
PT  - Journal Article
DEP - 20230310
PL  - Spain
TA  - Rev Esp Enferm Dig
JT  - Revista espanola de enfermedades digestivas
JID - 9007566
SB  - IM
EDAT- 2023/03/11 06:00
MHDA- 2023/03/11 06:00
CRDT- 2023/03/10 07:13
PHST- 2023/03/10 07:13 [entrez]
PHST- 2023/03/11 06:00 [pubmed]
PHST- 2023/03/11 06:00 [medline]
AID - 10.17235/reed.2023.9213/2022 [doi]
PST - aheadofprint
SO  - Rev Esp Enferm Dig. 2023 Mar 10. doi: 10.17235/reed.2023.9213/2022.